Xicheng Wang

机构：Yangtze University, Guangdong Pharmaceutical University, Peking University, Peking University Cancer Hospital, First Affiliated Hospital of Guangdong Pharmaceutical University, Shanghai East Hospital, Xuzhou Central Hospital · ORCID：0000-0002-2719-2538

发表论文 183 篇 · 总被引 3977 次 · h-index 29

代表论文

• Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025 · Journal of Clinical Oncology · 被引 55)
• Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers (2024 · Cancer Immunology Immunotherapy · 被引 17)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL) (2024 · Cell Reports Medicine · 被引 14)
• Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial (2025 · BMC Medicine · 被引 6)
• Circulating Tumor Cells Culture: Methods, Challenges, and Clinical Applications (2024 · Small Methods · 被引 5)